Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00989014
Other study ID # RD.06.SPR.18144
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date September 2009
Est. completion date December 2009

Study information

Verified date September 2013
Source Galderma R&D
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, double-blind, parallel-group, vehicle-controlled, dose-finding study to investigate the pharmacodynamics and the safety of three dosages of CD07805/47 topical gel (0.07%, 0.18%, and 0.50%), after a single application in subjects with a clinical diagnosis of stable moderate to severe erythematotelangiectatic rosacea. Subjects will be randomized in a 1:1:1:1 ratio to receive either one of three CD07805/47 topical gel concentrations (0.07%, 0.18%, or 0.50%) or Vehicle Gel. All subjects will be treated with a single application (once daily dosing for one day) of study medication.


Recruitment information / eligibility

Status Completed
Enrollment 122
Est. completion date December 2009
Est. primary completion date November 2009
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Male or female who is at least 18 years of age. - Clinical diagnosis of stable moderate to severe erythematotelangiectatic rosacea. - CEA (clinician's erythema assessment) score greater than or equal to 3 at Screening and on Treatment visit at baseline. - PSA (patient self assessment) score of greater than or equal to 3 at Screening and on Treatment visit at baseline. - Presence of 2 or fewer inflammatory facial lesions. Exclusion Criteria: - History of Raynaud's Syndrome, glaucoma, orthostatic hypotension, thromboangiitis obliterans, cerebral or coronary insufficiency, or depression. - History of refractive surgery such as photorefractive keratectomy. - The subject is being treated with monoamine oxidase (MAO) inhibitor, anti-depressants, barbiturates, opiates, sedatives, systemic anesthetics, alpha-agonists, beta blockers, antihypertensive agents, cardiac glycosides, or systemic anticoagulants. - The subject is currently enrolled in an investigational drug or device study or participated in such a study in the past 3 months prior to enrollment and is still in the exclusion period on the day of the Treatment visit.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
CD07805/47
0.5% Topical Gel
CD07805/47
0.18% Topical Gel
CD07805/47
0.07% Topical Gel
CD07805/47 placebo
Vehicle Topical Gel

Locations

Country Name City State
United States Derm Research, Inc Austin Texas
United States J&S Studies College Station Texas
United States Philadephia Institute of Dermatology Fort Washington Pennsylvania
United States Burke Pharmaceutical Research Hot Springs Arkansas
United States The Education & Research Foundation Lynchburg Virginia

Sponsors (1)

Lead Sponsor Collaborator
Galderma R&D

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Response Rate for Achieving a 2 Grade Improvement on Clinician's Erythema Assessment (CEA) and Patient Self Assessment (PSA) Over 12 Hours After Dosing. Baseline and every hour for 12 hours following application
See also
  Status Clinical Trial Phase
Terminated NCT03708263 - Evaluation of the New Laser PHOTOLASE PLV-585nm for the Treatment of Rosacea N/A
Completed NCT02268474 - Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea N/A
Completed NCT01756027 - Feasibility Study: Ulthera System for the Treatment of Rosacea N/A
Completed NCT06331533 - Intradermal BoNT-A Treatment in Erythematotelangiectatic Rosacea Phase 4
Completed NCT02144181 - Ultherapy® for the Treatment of Erythematotelangiectatic Rosacea N/A
Recruiting NCT05360251 - Pulsed Dye Laser and Intense Pulsed Light Configured With Different Wavelength Bands in Improving Erythematotelangiectatic Rosacea N/A
Completed NCT01045551 - Open Label Pilot Study of Apremilast in Treatment of Rosacea Phase 2
Completed NCT00945373 - Combination Therapy for the Treatment of Rosacea Phase 1
Completed NCT04153188 - Pulsed Dye Laser Treatment and Oxymetazoline Hydrochloride (HCL) 1% Cream for Erythematotelangiectatic Rosacea Phase 4
Completed NCT02393937 - A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea Phase 3
Completed NCT02052999 - Study to Evaluate the Efficacy and Safety of PAC-14028 Cream in Rosacea Patients Phase 2